Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lakeway, TX, US. The stock last traded at $0.30, up 0.00% on the session, giving a market capitalisation of $12.2M. On trailing twelve-month figures it carries a trailing P/E of -1.54, a net margin of 0.0%. Its beta of -1.82 implies it has historically moved less than the broad market.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. is most often compared with the following Healthcare names: